IP Verse

Bifunctional Polypeptides - EP3112377

The patent EP3112377 was granted to Immunocore on Apr 18, 2018. The application was originally filed on May 19, 2010 under application number EP16176249A. The patent is currently recorded with a legal status of "Revoked".

EP3112377

IMMUNOCORE
Application Number
EP16176249A
Filing Date
May 19, 2010
Status
Revoked
Aug 6, 2021
Grant Date
Apr 18, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBJan 15, 2019-ADMISSIBLE

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO03020763
OPPOSITIONUS2004253632
OPPOSITIONUS2009042285
OPPOSITIONWO0193913
OPPOSITIONWO03020763
OPPOSITIONWO2004033685
OPPOSITIONWO2004074322
OPPOSITIONWO2006037960
OPPOSITIONWO2008135734
SEARCHUS2004253632
SEARCHWO0193913
SEARCHWO03020763
SEARCHWO2004074322
SEARCHWO2005113595
SEARCHWO2006037960
SEARCHWO9960120

Non-Patent Literature (NPL) Citations (23) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BELMONT HJ. ET AL., CLIN IMMUNOL, (2006), vol. 121, no. 1, pages 29 - 39-
DESCRIPTION- CHAMES P. ET AL., PROC NATL ACAD SCI U S A, (2000), vol. 97, no. 14, pages 7969 - 74-
DESCRIPTION- DENKBERG G. ET AL., J IMMUNOL, (2003), vol. 171, no. 5, pages 2197 - 207-
DESCRIPTION- MARGET M. ET AL., MOL LMMUNOL, (2005), vol. 42, no. 5, pages 643 - 9-
DESCRIPTION- MOSQUERA LA. ET AL., J IMMUNOL, (2005), vol. 174, no. 7, pages 4381 - 8-
DESCRIPTION- NEETHLING FA. ET AL., VACCINE, (2008), vol. 26, no. 25, pages 3092 - 102-
DESCRIPTION- PAN, BIOTECHNIQUES, (2000), vol. 29, no. 6, pages 1234 - 8-
DESCRIPTION- PAN ET AL., BIOTECHNIQUES, (2000), vol. 29, no. 6, pages 1234 - 8-
DESCRIPTION- WEN J. ET AL., CANCER IMMUNOL IMMUNOTHER, (2008), vol. 57, no. 12, pages 1781 - 94-
DESCRIPTION- WEN J. ET AL., CANCER IMMUNOL LMMUNOTHER, (2008), vol. 57, no. 12, pages 1781 - 94-
DESCRIPTION- WILLEMSEN RA. ET AL., J IMMUNOL, (2005), vol. 174, no. 12, pages 7853 - 8-
DESCRIPTION- WILLEMSEN R. ET AL., CYTOMETRY A, (2008), vol. 73, no. 11, pages 1093 - 9-
OPPOSITION- PENG LS et al., "A single-chain IL -12 IgG3 an- tibody fusion protein retains anti- body specificity and IL -12 bioac- tivity and demonstrates antitumor activity", J Immunol., (19990701), vol. 163, no. 1, pages 250 - 258, XP002967832-
OPPOSITION- CARD KF et al., "A soluble single- chain T- cell receptor IL -2 fusion protein retains MHC-restricted peptide specificity and IL -2 bioac- tivity", Cancer Immunol Immu- nother, (20040000), vol. 53, pages 345 - 357, XP002351550
OPPOSITION- WEN J et al., "Targeting activity of a TCR/ IL -2 fusion protein against established tumors", Cancer Immu- nol Immunother, (20081200), vol. 57, no. 12, pages 1781 - 1794, XP019654552
OPPOSITION- ARGOS P, "An investigation of oligo- peptides linking domains in protein tertiary structures and possible can- didates for general gene fusion", J Mol Biol., (19900220), vol. 211, no. 4, pages 943 - 958, XP009043079
OPPOSITION- DENKBERG G et al., "Recombinant antibodies with T- cell receptor-like specificity: novel tools to study MHC class I presen- tation", Autoimmun Rev., (20060400), vol. 5, no. 4, pages 252 - 257, XP005428923
OPPOSITION- MOLLOY PE et al., "Soluble T cell receptors: novel immunotherapies", Curr Opin Phar- macol, (20050800), vol. 5, no. 4, pages 438 - 443, XP004969013
OPPOSITION- JONATHAN M. BOULTER et al., "Stable, soluble T- cell receptor molecules for crys- tallization and therapeutics", Pro- tein Engineering, (20030901), vol. 16, no. 9, pages 707 - 711, XP002275339
OPPOSITION- ORTIZ-SANCHEZ E et al., "Antibody- cytokine fusion proteins: applica- tions in cancer therapy", Expert Opin Biol Ther., (20080000), vol. 8, no. 5, pages 609 - 632, XP008145785
SEARCH- SCHLITT H J ET AL, "DIFFERENT ACTIVATION STATES OF HUMAN LYMPHOCYTES AFTER ANTIBODY-MEDIATED STIMULATION VIA CD3 AND THE ALPHA-BETA T CELL RECEPTOR", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, (1990), vol. 32, no. 6, ISSN 0300-9475, pages 717 - 726, XP002600946 [A] 1-9 * abstract *-
SEARCH- LI BOHUA ET AL, "Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions", IMMUNOLOGY, (200512), vol. 116, no. 4, ISSN 0019-2805, pages 487 - 498, XP002600947 [A] 1-9 * abstract *
SEARCH- BIBOLLET-RUCHE FREDERIC ET AL, "The Quality of Chimpanzee T-Cell Activation and Simian Immunodeficiency Virus/Human Immunodeficiency Virus Susceptibility Achieved via Antibody-Mediated T-Cell Receptor/CD3 Stimulation Is a Function of the Anti-CD3 Antibody Isotype", JOURNAL OF VIROLOGY, (200810), vol. 82, no. 20, ISSN 0022-538X, pages 10271 - 10278, XP002600945 [A] 1-9 * abstract * * page 10272, column 1, paragraph 4 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents